Infection Clinical Trial
Official title:
The Effect of Combined General-epidural vs General Anaesthesia on Postoperative Intestinal Function Recovery and Infection in Neonates and Infants Undergoing Gastrointestinal Surgery: a Prospective, Randomised, Controlled Trial
Sixty neonates and infants will be enrolled and randomised into two groups of n=30 each .
For their surgical procedures, one group general (GA) anaesthesia the second group will
receive a combined general and epidural anaesthesia (CGEA).
Anaesthetic technique:
Patients in the GA group will be induced with intravenous propofol (2-4 mg.kg-1) and
fentanyl (2-4 µg.kg-1) and will receive rocuronium bromide (0.5 mg.kg-1) to facilitate
endotracheal intubation. Anaesthesia will be maintained with sevoflurane (2-3%) in an
air/oxygen mixture as well as intravenous fentanyl as required.
In the (CGEA) 0.5 ml.kg-1 of 0.25% bupivacaine will be injected into the epidural catheter,
followed by a continuous infusion of 0.1% bupivacaine at a rate of 0.2 mg.kg-1.hr-1 for up
to 48 hours postoperatively. Assessment of anaesthetic efficacy will be measured
Intraoperative care vital signs. And will continuously be monitored with a Datex AS/3
(Engestrom®, Helsinki, Finland) monitor.
The use of antibiotic prophylaxis will be determined by the degree of bowel contamination
during surgery, with the commonest regimen consisting of penicillin, gentamicin and
metronidazole will be administered. Antibiotics will be continued for 36-48 hours
postoperatively to prevent infection arising from the disturbed bowel flora.
Postoperative care, following surgery, will be conducted. The feeding volume will be
increased in steps as long as the volume of regurgitated fluid will be less than 20% of the
administered breast milk or formula volume. Full feeding will define as oral tolerance of at
least 80% of daily maintenance volume. In cases of abdominal distension or vomiting, feeding
will withheld until symptom resolution. The nasogastric tube will be removed on bowel
function restoration The CRIES score will be use to assess the severity and duration of
postoperative pain during the patients' NICU stay. If the CRIES score is ≥4, fentanyl will
be continuously intravenously infused in both study group. Fentanyl will be also
administered to CGEA patients who experienced pain despite a continuous epidural infusion at
1-5 µg.kg-1.h-1. The amount of fentanyl required for adequate postoperative pain relief will
be recorded in both groups.
After approval off the local Ethical Committee of Bnai Zion Hospital, Haifa, Israel and
informed parental consent obtained for each participant. Sixty small infants who undergoing
GI surgery will be enrolled in this study.
The inclusion criteria are neonates or infants requiring the following major intestinal
procedures: duodenoduodenostomy or duodenojejunostomy for duodenal atresia, ileocaecal
resection for intestinal volvulus, ileostomy or colostomy closure for congenital anorectal
malformations, and corrective surgery for Hirschsprung's disease. The exclusion criteria are
concurrent coagulopathies, sepsis, vertebral column malformations, neurological disease,
immunocompromise with or without leukopenia, and intestinal necrotising enterocolitis.
Patients will be also excluded if they will require exploratory laparotomy or emergent
intestinal surgery.
Sixty premature, ex-premature, and full-term neonates and infants meeting the above criteria
will enrolled in the study, patients will randomised into two groups of n=30 each (
according to a computer program ) . For their surgical procedures, the first group will
receive general anesthesia (GA group), whereas the second group receive combined general and
epidural anesthesia (CGEA group).
Anesthetic technique Patients in the GA group will be induced with intravenous propofol (2-4
mg.kg-1) and fentanyl (2-4 µg.kg-1) and receive rocuronium bromide (0.5 mg.kg-1) to
facilitate endotracheal intubation. Anaesthesia will be maintained with sevoflurane (2-3%)
in an air/oxygen mixture as well as intravenous fentanyl as required.
Patients in the CGEA group will be induce as above in addition to receiving epidural
anaesthesia as follows: A 20G epidural catheter (B. Braun Medical Ltd., Melsungen, Germany)
through a 19G Crawford epidural needle, so that its tip lays between the desired T5 and T10
spinal segments. Correct catheter placement will be confirmed by portable epidurography
after filling the catheter with 0.5 ml iohexol (Omnipaque® 300, Nycomed, Oslo, Norway). A
test dose of 0.1 ml.kg-1 of 1% lidocaine with 1:200 000 adrenaline will be administered, and
the result and effects on heart rate (HR) and the ST segment will be noted. If the HR
increases by at least 20% above baseline and/or ST segment changes will be observed, the
catheter will be withdrawl and re positioned. 0.5 ml.kg-1 of 0.25% bupivacaine will be
injected into the epidural catheter, followed by a continuous infusion of 0.1% bupivacaine
at a rate of 0.2 mg.kg-1.hr-1 for up to 48 hours postoperatively.
Assessment of anesthetic efficacy in both groups will be confirmed by the absence of surges
in blood pressure (BP) and HR beyond 20% above baseline. Success of epidural anesthesia will
be defined by the correct placement of the epidural catheter between the T5 and T10 spinal
segments within two attempts, as well as the obviation for additional systemic analgesia. In
cases of epidural technique failure, anesthesia will be maintained by GA and the patient
will be removed from the study.
Intraoperative care Intraoperative systolic, diastolic and mean arterial pressures (SBP,
DBP, and MAP), HR, arterial oxygen saturation(SaO2), and temperature will be continuously
monitored with a Datex AS/3 (Engestrom®, Helsinki, Finland) monitor. All patients in the GA
group will mechanically be ventilated, with maintenance of peak inspiratory pressure between
18 and 30 cmH20, and end-tidal CO2 (ETCO2) between 30 and 50 mmHg. Additionally, urine
output will be measured at 30-minute intervals.
Two peripheral intravenous cannulae will be inserted preoperatively for each patient, and
fluid will be maintained with Ringer's lactate and 5% glucose solutions at 4 ml.kg-1.h-1.
Additional Ringer's lactate will be infused for fluid replacement of third-space and/or
blood losses. Packed red blood cells will be transfused in cases of blood loss ≥10% of blood
volume.
The use of antibiotic prophylaxis will be determined by the degree of bowel contamination
during surgery, with the commonest regimen consisting of penicillin, gentamicin and
metronidazole will be administered. Antibiotics will continue for 36-48 hours
postoperatively to prevent infection arising from the disturbed bowel flora.
Postoperative care following surgery, all patients will be transferred to the neonatal
intensive care unit (NICU) where physiological monitoring and mechanical ventilation will
continue as appropriate. Blood samples will be collected postoperatively for full blood
count, glucose, electrolyte, and blood gas measurement.
The feeding volume will be increased in 5 ml steps as long as the volume of regurgitated
fluid is less than 20% of the administered breast milk or formula volume. Full feeding will
be defined as oral tolerance of at least 80% of daily maintenance volume. In cases of
abdominal distension or vomiting, feeding will withheld until symptom resolution. The
nasogastric tube will be removed on bowel function restoration (i.e. defaecation).
The CRIES neonatal postoperative pain score (C=Crying; R=Requires oxygen; I=Increased vital
signs; E=Expression; S=Sleepless) [18] will be used to assess the severity and duration of
postoperative pain during the patients' NICU stay. Scoring will carried out by the attending
nurses every two hours. If the CRIES score is ≥4, fentanyl will be continuously
intravenously infused in both study group. Fentanyl will be also administered to CGEA
patients who experienced pain despite a continuous epidural infusion at 1-5 µg.kg-1.h-1. The
amount of fentanyl required for adequate postoperative pain relief will recorded in both
groups.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04529421 -
Assocation Between In-person Instruction and COVID-19 Risk
|
||
Recruiting |
NCT04081792 -
Optimal Antibiotics for Operated Diabetic Foot Infections
|
N/A | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Recruiting |
NCT04674657 -
Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
|
||
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Recruiting |
NCT00342589 -
New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
|
||
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Completed |
NCT03296423 -
Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly
|
Phase 4 | |
Withdrawn |
NCT04217252 -
Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection
|
N/A | |
Recruiting |
NCT02905552 -
Myelodysplasic Syndromes and Risk Factors for Infection
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Withdrawn |
NCT02904434 -
Gastrointestinal Implications of Voriconazole Exposure
|
||
Active, not recruiting |
NCT02768454 -
Antimicrobials Stewardship by Pharmacist
|
N/A | |
Completed |
NCT02219776 -
Decreasing Infection In Arthroscopic Shoulder Surgery
|
N/A | |
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Recruiting |
NCT02098226 -
Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts
|
N/A | |
Completed |
NCT01846832 -
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
|
Phase 3 | |
Completed |
NCT01434797 -
Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
|
||
Terminated |
NCT01441206 -
Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants
|
Phase 1 | |
Completed |
NCT01159834 -
Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)
|
N/A |